Concurrent Radiation Therapy With the Antibody-Drug Conjugates Brentuximab Vedotin and Polatuzumab Vedotin

Abstract

lesion and 2 had multiple lesions. None had active extracranial disease. Median pre-SRT Karnofsky Performance Status (KPS) was 60 (range 50 − 90). All 7 patients completed SRT and received concurrent and adjuvant ICI therapy. Median follow-up after completion of SRT was 9.1 months. Acute toxicities of SRT and ICI therapy were minimal, including fatigue (3 patients), diarrhea (2), and adrenal insufficiency requiring oral steroids (1). Five patients (71.4%) achieved symptomatic improvement after SRT including 2 patients (28.5%) with a clinical complete response (CR). Median post-SRT KPS was 70 (range: 60 − 100). Six patients had followup imaging, and all had an objective response including 3 (50%) with a radiographic CR. The median time to best radiographic response was 2.0 months (range 0.3 − 3.7 months), and all treated lesions remained controlled on all subsequent imaging. Three patients (42.9%) experienced outof-field intracranial recurrence. Median PFS was 7.7 months (95% CI: 4.0 − 11.4 months) and median OS was 12.6 months (95% CI: 7.5 − 12.7 months) post-SRT. Conclusion: Among patients with relapsed or refractory CNSL, SRT + ICI appears to be well tolerated and offers excellent symptomatic and radiographic local control. Further studies are needed to identify appropriate candidates for salvage SRT + ICI, and to evaluate the clinical efficacy and neurocognitive impact of this approach.

Stable use of radiotherapy in lymphoma patients over time – A comprehensive national overview of radiotherapy use in Sweden with focus on older patients

“…The encouraging RS seen in selected lymphoma patients receiving RT, and the reduced risk of side effects and second malignancies with modern RT concepts, should encourage future clinical trials and continued inclusion of RT as a treatment option in national and international guidelines [30] . Newer studies also show the safety of combining RT with novel targeted drugs and immunotherapy [31] , [32] .…”

Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond

“…On the other hand, one report recently documented a transient CR in a patient with ALCL using BV + RT [70]. Another retrospective analysis instead evaluated the safety of BV + RT in 12 patients with MF, with or without large cell transformation [71]. Ten patients with DLBCL treated with a combination of polatuzumab vedotin and RT were also included.…”